S&P 500 7,745 -0.10% Nasdaq 26,645 +0.15% Dow Jones 53,460 -0.96% FTSE 100 10,711 -1.23% DAX 26,219 -0.65% Nikkei 225 67,461 -0.09% Hang Seng 25,471 -0.71% WTI Crude 84.12 +3.53% Gold 4,454 +2.07% US 10-Year Treasury Yield 4.724 +0.85% S&P 500 7,745 -0.10% Nasdaq 26,645 +0.15% Dow Jones 53,460 -0.96% FTSE 100 10,711 -1.23% DAX 26,219 -0.65% Nikkei 225 67,461 -0.09% Hang Seng 25,471 -0.71% WTI Crude 84.12 +3.53% Gold 4,454 +2.07% US 10-Year Treasury Yield 4.724 +0.85%

LATEST

THL to buy website traffic management business from GRO; Columna in strategic exit from Swiss dental group●The CEO of KB Home has a plan to tempt first-time buyers into the market at last●Bolivia Links Large-Buyer Diesel to World Prices●Chinese treasury futures launch cements Hong Kong as premier yuan hub●Low PE stock Felix Industries jumps over 3% despite muted trends on Dalal Street●US 30-year yields hit highest level since 2007 as war and oil worries fester●These six insurers missed NAICOM recapitalisation deadline, face uncertain future●Is market heading towards a big AI crash like the dot-com crisis? Here's what European Central Bank predicts●THL to buy website traffic management business from GRO; Columna in strategic exit from Swiss dental group●The CEO of KB Home has a plan to tempt first-time buyers into the market at last●Bolivia Links Large-Buyer Diesel to World Prices●Chinese treasury futures launch cements Hong Kong as premier yuan hub●Low PE stock Felix Industries jumps over 3% despite muted trends on Dalal Street●US 30-year yields hit highest level since 2007 as war and oil worries fester●These six insurers missed NAICOM recapitalisation deadline, face uncertain future●Is market heading towards a big AI crash like the dot-com crisis? Here's what European Central Bank predicts●

Asia

Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjector

Markets-Economic Times · 2h ago · 🇮🇳 India

Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjector

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.

Read the full story at Markets-Economic Times →

More Asia

Chinese treasury futures launch cements Hong Kong as premier yuan hub

Business - South China Morning Post · 26m ago

Low PE stock Felix Industries jumps over 3% despite muted trends on Dalal Street

mint - markets · 29m ago

US 30-year yields hit highest level since 2007 as war and oil worries fester

Markets-Economic Times · 32m ago

Is market heading towards a big AI crash like the dot-com crisis? Here's what European Central Bank predicts

Markets-Economic Times · 37m ago